CYPENZA - A prospective cohort trial on antiandrogens influences on the pharmacokinetics of corticosteroids.
Key facts
- Where
- Umea, SvédországSee the site
- Phase
- 3. fázis
Where in Svédország
- Region VaesterbottenUmea, SvédországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Vaesterbotten
- Trial code
- EU 2025-520571-66-00
- Record updated
- 2026. június 11.
- Original description
To assess the extent to which the antiandrogens (enzalutamide and apalutamide) influence the pharmacokinetics of the administered corticosteroid dexamethasone.Read full original descriptionShow less
To assess the extent to which the antiandrogens (enzalutamide and apalutamide) influence the pharmacokinetics of the administered corticosteroid dexamethasone.
Inclusion: Diagnosed prostate cancer; Intended to begin treatment with antiandrogen therapy, -enzalutamide or apalutamide-; Can understand all the requirements of the trial, provide informed consent, and provide authorization of use and disclosure of personal health information; WHO performance status 0-1.
Exclusion: Treatment with systemic corticosteroids (ongoing or last 4 weeks), inhalations steroids, topical steroids or nasal steroids are not regarded as systemic therapies; Treatment with health product modulating CYP3A4; Treatment with warfarin or NOAC (Non-vitamin K-antagonist anticoagulants); Previous seizure in medical history; Diabetes (defined as diagnosed diabetes type I or type II); Other serious illness or medical condition according to the investigator, e.g., other cancer, history of peptic ulcer, or bipolar disorder.